C4 Therapeutics price target raised to $50 from $39 at Brookline

Brookline raised the firm’s price target on C4 Therapeutics (CCCC) to $50 from $39 and keeps a Buy rating on the shares. The firm fine-tuned its valuation for 2025 and said it expects C4 Therapeutics will have completed the CFT7455 phase I dose exploration in relapsed/refractory multiple myeloma and r/r non-Hodgkin’s lymphomas by the year-end. C4 is likely to provide multiple readouts for CFT1946 monotherapy data this year, including fully monotherapy CFT1946 dose escalation cohorts in BRAF V600 mutant solid tumors, the analyst tells investors in a research note.